Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1115-1123

  Yang, Cao ^a,b   Choy, Edwin ^b   Hornicek, Francis J ^b   Wood, Kirkham B ^b   Schwab, Joseph H ^b   Liu, Xianzhe ^a,b   Mankin, Henry ^b   Duan, Zhenfeng ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Histone deacetylase inhibitor; Multidrug resistant; PCI 24781; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DOXORUBICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 ALPHA; HISTONE; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PCI 24781; PM 00104; PROTEIN P21; RAD51 PROTEIN; TRABECTEDIN; UNCLASSIFIED DRUG; ZALYPSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ACTIVITY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; BLOTTING, WESTERN; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NUCLEAR PROTEINS; P-GLYCOPROTEINS; POLY(ADP-RIBOSE) POLYMERASES; SARCOMA;

EID: 79956061602     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Steinert DM, Blakely LJ, Salganick J and Trent JC: Molecular targets in therapy for human soft-tissue and bone sarcomas. Curr Oncol Rep 5: 295-303, 2003. (Pubitemid 38898796)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
3. Trent JC: Rapid evolution of the biology and treatment of sarcoma. Curr Opin Oncol 20: 393-394, 2008.
4. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs 10: 315-327, 2008.
5. Kasper B, Gil T and Awada A: Treatment of patients with advanced soft tissue sarcoma: Disappointment or challenge? Curr Opin Oncol 19: 336-340, 2007.
6. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B and Alman BA: Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8: 513-524, 2007. (Pubitemid 46823060)
7. Fojo T and Bates S: Strategies for reversing drug resistance. Oncogene 22: 7512-7523, 2003. (Pubitemid 37487173)
8. Duan Z, Brakora KA and Seiden MV: Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 3: 833-838, 2004. (Pubitemid 39193765)
9. van Vlerken LE, Duan Z, Seiden MV and Amiji MM: Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug-resistance in cancer. Cancer Res 67: 4843-4850, 2007. (Pubitemid 46910193)
10. Smith KT and Workman JL: Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 41: 21-25, 2009.
11. Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17, 2008.
12. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG and Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
13. Rosato RR, Almenara JA, Dai Y and Grant S: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2: 1273-1284, 2003.
14. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET and Gannon F: Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24: 4894-4907, 2005. (Pubitemid 41129094)
15. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET and Gannon F: Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 27: 1376-1386, 2008.
16. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003. (Pubitemid 37413470)
17. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
18. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671, 2007.
19. Arnold NB, Arkus N, Gunn J and Korc M: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18-26, 2007. (Pubitemid 46121848)
20. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC and Jiang SW: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5: 2767-2776, 2006. (Pubitemid 44849003)
21. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P and Bhalla K: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984, 2003.
22. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M and Echigo S: Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 30: 1181-1188, 2007.
23. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR and Dalrymple SA: CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5: 1309-1317, 2006. (Pubitemid 43881324)
24. Banuelos CA, Banath JP, MacPhail SH, Zhao J, Reitsema T and Olive PL: Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res 13: 6816-6826, 2007. (Pubitemid 350206820)
25. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM and Buggy JJ: HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 104: 19482-19487, 2007.
26. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE and Lev DC: Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15: 3472-3483, 2009.
27. Yang C, Yang S, Wood KB, Hornicek FJ, Schwab JH, Fondren G, Mankin H and Duan Z: Multidrug-resistant osteosarcoma cell lines exhibit deficiency of GADD45α expression. Apoptosis 14: 124-133, 2009.
28. Lourda M, Trougakos IP and Gonos ES: Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein J. Int J Cancer 120: 611-622, 2007. (Pubitemid 44969033)
29. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P and Scotlandi K: The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 27: 1605-1616, 2005.
30. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L, Vilanova D, Lopez-Corral L, Montero JC, Hernandez-Iglesias T, de Alava E, Galmarini C, Aviles P, Cuevas C, San-Miguel JF and Pandiella A: Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113: 3781-3791, 2009.
31. Benson FE, Stasiak A and West SC: Purification and characterization of the human RAD51 protein, an analogue of E. coli RecA. EMBO J 13: 5764-5771, 1994. (Pubitemid 24363044)
32. Baumann P, Benson FE and West SC: Human RAD51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87: 757-766, 1996. (Pubitemid 26386948)
33. Gupta RC, Bazemore LR, Golub EI and Radding CM: Activities of human recombination protein RAD51. Proc Natl Acad Sci USA 94: 463-468, 1997. (Pubitemid 27053656)
34. Mohrenweiser HW, Wilson DM, 3rd, and Jones IM: Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 526: 93-125, 2003. (Pubitemid 36507216)
35. Richardson C: RAD51, genomic stability, and tumorigenesis. Cancer Lett 218: 127-139, 2005.
36. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK and Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528, 2005. (Pubitemid 40261815)
37. Singh TR, Shankar S and Srivastava RK: HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24: 4609-4623, 2005. (Pubitemid 41032599)
38. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705, 2002. (Pubitemid 34994462)
39. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV and Castronovo V: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436, 2002. (Pubitemid 34123805)
40. Takekawa M and Saito H: A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 95: 521-530, 1998. (Pubitemid 28533308)
41. Miyake Z, Takekawa M, Ge Q and Saito H: Activation of MTK1/MEKK4 by GADD45 through induced N-C dissociation and dimerization-mediated trans-autophosphorylation of the MTK1 kinase domain. Mol Cell Biol 27: 2765-2776, 2007. (Pubitemid 46581364)
42. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM and Pastan I: The human multidrug resistance (MDR1) gene. cDNA cloning and transcription initiation. J Biol Chem 262: 505-508, 1987. (Pubitemid 17005205)